Your browser doesn't support javascript.
Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline.
Laemmle-Ruff, Ingrid; Lewis, Georgina; Clothier, Hazel J; Dimaguila, Gerardo Luis; Wolthuizen, Michelle; Buttery, Jim; Crawford, Nigel W.
  • Laemmle-Ruff I; SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Lewis G; SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Clothier HJ; SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Dimaguila GL; Melbourne School of Population & Global Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia.
  • Wolthuizen M; Centre for Health Analytics, Melbourne, VIC, Australia.
  • Buttery J; SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Crawford NW; Centre for Health Analytics, Melbourne, VIC, Australia.
Front Public Health ; 10: 1053637, 2022.
Article in English | MEDLINE | ID: covidwho-2123482
ABSTRACT
Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC), Victoria's vaccine safety service for reporting adverse events following immunisation (AEFI), has provided integrated spontaneous surveillance and clinical services for individuals affected by AEFI since 2007. We describe SAEFVIC's response to the COVID-19 vaccine program, and reflect on lessons learned for vaccine safety. The massive scale of the Australian COVID-19 vaccine program required rapid adaptations across all aspects of SAEFVIC's vaccine safety services. Collection of AEFI reports was streamlined and expanded, incorporating both spontaneous and active surveillance data. Dramatically increased report volumes were managed with additional staffing, and innovations to automate, filter, and triage reports for priority follow up. There were two major adverse events of special interest (AESI) thrombosis with thrombocytopaenia syndrome and myocarditis, with multiple other AESI also investigated. Rapid escalation mechanisms to respond to AESI were established, along with AESI-specific databases for enhanced monitoring. Vaccine education and training resources were developed and public-facing vaccine safety reports updated weekly. Frequent communication with local and national government and regulatory bodies, and consultation with specialist groups was essential. The COVID-19 vaccine program has highlighted the importance of vaccine safety in supporting public confidence in vaccines and informing evidence-based immunisation policy. Supporting the COVID-19 vaccine program has required flexibility in adapting to policy changes and evolving vaccine safety signals, careful triage and prioritisation, informatics innovation, and enhanced engagement with the public regarding vaccine safety. Long-term investment to continue strengthening vaccine safety systems, building on lessons learned, will be essential for the ongoing success of Australian vaccination programs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Oceania Language: English Journal: Front Public Health Year: 2022 Document Type: Article Affiliation country: Fpubh.2022.1053637

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Oceania Language: English Journal: Front Public Health Year: 2022 Document Type: Article Affiliation country: Fpubh.2022.1053637